Published in Human Psychopharmacology in 2012, researchers conducted a meta-analysis specifically examining whether Ginkgo biloba - one of the world''s best-selling cognitive supplements - actually enhances cognition in healthy people.

They identified randomized controlled trials providing data on memory (13 studies, 1,132 participants), executive function (7 studies, 534 participants), and attention (8 studies, 910 participants). The results were unambiguous: effect sizes were essentially zero across all three cognitive domains. Memory showed d = -0.04, executive function showed d = -0.05, and attention showed d = -0.08 - none statistically significant and all effectively no different from placebo.

Meta-regressions showed that the null results were not explained by participant age, trial duration, daily dose, total dose, or sample size. No matter how the data was sliced - younger or older people, higher or lower doses, shorter or longer supplementation periods - Ginkgo biloba provided no cognitive benefit to healthy individuals.

Published in the Journal of Cognitive Enhancement in 2024, researchers tested CILTEP - a commercially available nootropic supplement marketed as improving memory, focus, and motivation - in a randomized, double-blind, placebo-controlled study with 33 healthy middle-aged and older participants.

CILTEP is a stack containing artichoke extract, forskolin, acetyl-L-carnitine, vitamin B6, and L-phenylalanine. It is widely sold online with claims of enhancing long-term potentiation (the brain''s mechanism for forming memories) and increasing dopamine and cAMP levels.

Despite these marketing claims, the study found no significant improvement on any cognitive measure compared to placebo. Tests covered attention, memory, processing speed, and executive function. The results were uniformly null - CILTEP performed no better than an inert pill across every cognitive domain tested. The authors concluded there is no evidence supporting the marketed cognitive enhancement claims for this product.

Published in the EFSA Journal in 2024, the European Food Safety Authority (EFSA) - the EU''s independent food safety agency - evaluated a health claim application proposing that creatine supplementation improves cognitive function in healthy adults.

After reviewing the submitted evidence, the EFSA panel concluded that the evidence for a mechanism by which continuous creatine consumption could improve cognitive performance in healthy adults is weak. This applies both to normal conditions and stressed conditions such as sleep deprivation. The panel did not approve the proposed health claim.

This is significant because EFSA evaluates health claims with rigorous standards - they require consistent evidence from well-designed human intervention studies showing a cause-and-effect relationship. The fact that they found the creatine-cognition evidence "weak" means that despite individual positive studies, the overall body of evidence does not meet the threshold for reliable, reproducible cognitive enhancement in the general healthy population.

Published in Complementary Therapies in Clinical Practice in 2024, researchers conducted a systematic review and meta-analysis of piracetam for cognitive effects in adults with memory impairment. Piracetam was the first substance ever labeled a "nootropic" when the term was coined in 1972, and it remains one of the most studied cognitive enhancers.

Despite decades of research and widespread use, the meta-analysis found that memory enhancement showed no clinically meaningful difference between piracetam and placebo groups. The authors concluded that they "cannot definitively ascertain the impact of piracetam on memory function" based on the available evidence.

This is particularly notable because piracetam has been studied for over 50 years. If it had robust cognitive effects, they should have been clearly demonstrated by now. Earlier meta-analyses suggested some benefits, but those relied heavily on older studies with subjective outcome measures. When more recent, rigorous studies are included, the overall evidence collapses to essentially no detectable effect.

Published in the journal Nutrients in 2022, researchers reviewed the regulatory landscape of nootropic supplements and found fundamental problems with how these products reach consumers. Because nootropics are classified as dietary supplements rather than drugs, they bypass the rigorous clinical testing and approval process required by the FDA or EMA.

The review found that over 52% of nutraceutical retailers reported consumer confusion over safety claims and labeling accuracy. More than 46% of manufacturers reported delays in launching new products due to complex compliance hurdles. A lack of uniform standards and inconsistent quality control practices have resulted in widespread concerns about product safety.

This means that many nootropic products sold to consumers have never been tested in proper clinical trials, their ingredient amounts may not match labels, and their safety profiles are largely unknown. The supplements people buy may contain different doses than advertised, contaminants, or ingredients that interact dangerously with medications. Without regulatory oversight equivalent to pharmaceuticals, cognitive enhancement claims remain largely unverified marketing.

The Cochrane Collaboration - considered the gold standard for systematic reviews in medicine - conducted two separate reviews examining omega-3 fatty acid supplementation for cognitive function.

Both reviews concluded that supplemental omega-3 fatty acids do not enhance cognition in the general population. This finding directly contradicts the marketing of countless fish oil and DHA supplements sold with claims about "brain health" and "mental sharpness." The reviews included randomized controlled trials comparing omega-3 supplements to placebo in people without dementia or significant cognitive impairment.

A separate 2014 systematic review in the Cochrane database examining omega-3 for ADHD and learning disorders also found limited evidence of treatment benefits. Despite omega-3 supplements being a multi-billion-dollar industry with heavy marketing around cognitive benefits, the highest-quality evidence synthesis consistently shows no meaningful improvement in cognitive function for healthy people already consuming a normal diet.

Published in Frontiers in Nutrition in 2025, researchers conducted a double-blind, randomized, placebo-controlled study testing a standardized extract of Hericium erinaceus (lion''s mane mushroom) on cognition and mood in healthy younger adults.

The results showed that acute consumption of lion''s mane fruiting body did not produce a significant overall improvement in cognitive performance compared to placebo. Any benefits observed were limited to specific sub-tasks rather than general cognitive enhancement. Mood outcomes were similarly unaffected.

This is notable because lion''s mane has become one of the fastest-growing nootropic supplements, with extensive marketing claims about improving memory, focus, and mental clarity. The proposed mechanism - stimulating nerve growth factor (NGF) production - is biologically plausible but does not appear to translate into measurable cognitive improvement in healthy young people taking the supplement acutely. The authors concluded that any benefits may be task-specific or domain-specific rather than general cognitive enhancement.

Published in European Neuropsychopharmacology in 2020, researchers conducted a series of meta-analyses examining the acute cognitive effects of modafinil, methylphenidate, and d-amphetamine in healthy adults. These are pharmaceutical-grade substances - far more potent than over-the-counter supplements - yet even they showed only modest results.

The meta-analyses found that while some statistically significant effects existed, they were small in magnitude. The authors explicitly stated that "there is a user perception that these drugs are effective cognitive enhancers, but this is not supported by the evidence so far." The experiments included did not accurately reflect real-world use conditions in the wider population.

This finding is directly relevant to nootropic supplement claims because if even prescription-strength cognitive enhancers produce only small, inconsistent effects in healthy adults, it is highly unlikely that less potent dietary supplements would produce meaningful enhancement. The gap between perceived effectiveness (shaped by placebo effects, confirmation bias, and marketing) and actual measured effects was a central finding.

A systematic review of randomized controlled trials on Bacopa monnieri - often cited as the nootropic with the strongest evidence - found that only 6 studies met rigorous inclusion criteria. All trials lasted 12 weeks and used dosages of 300 to 450 mg of extract per day.

Across these 6 studies, Bacopa improved performance on 9 of 17 tests measuring memory free recall (the ability to remember a list of items without cues). However, there was little evidence of enhancement in any other cognitive domain including attention, executive function, working memory, processing speed, or verbal fluency.

This means that even for Bacopa - the "best case" nootropic supplement - the benefits are limited to one narrow aspect of memory, not the broad cognitive enhancement suggested by marketing. People buying Bacopa expecting improved focus, clearer thinking, or better problem-solving are unlikely to experience those specific benefits based on the clinical evidence. The supplement may slightly help with memorizing lists, but that is a far cry from "enhanced cognitive function."